Fennec announces new PEDMARK data at ASCO showing hearing loss reduction in pediatric/AYA patients

FENNEC PHARMACEUTICALS INC.

Phase 2/3 STS-J01 study met primary endpoint: hearing loss 16-24% vs 56-63% historical control.
Randomized Phase 1 trial of cisplatin +/- PEDMARK for metastatic germ cell tumor opened at City of Hope.
Retrospective case series (9 AYA patients) shows PEDMARK feasible and does not compromise cisplatin antitumor activity.
Real-world data in 15 head & neck cancer adults: PEDMARK safe ≥6h after cisplatin, hearing preserved.
Company expands evidence base for PEDMARK in broader populations beyond current pediatric approval.

item 8.01 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-065696
form_type: 8-K
ticker: FENC
cik: 0001211583
company_name: FENNEC PHARMACEUTICALS INC.
filed_at: 2026-05-22T20:05:17+00:00
discovered_at: 2026-05-22T20:07:00.267305+00:00
generated_at: 2026-05-22T21:18:43.157153+00:00
sec_items: ["8.01", "7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-065696
json_url: https://secwatch.observer/filing/0001104659-26-065696.json
markdown_url: https://secwatch.observer/filing/0001104659-26-065696.md
text_url: https://secwatch.observer/filing/0001104659-26-065696.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465926065696/0001104659-26-065696-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465926065696/fencf-20260521x8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-26-065696

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.